Cavatak: Interim Phase II data

Interim data from 13 evaluable patients with stage IIIc/IV malignant melanoma in the first stage of a 2-stage, open-label,

Read the full 199 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE